Replies to post #12627 on Decision Diagnostics Corp (DECN)

[icbeatsthestreet]

I read it as that he is making a distinction between DECN and smaller players who have their own glucose monitoring devices and strips. DECN has a 26% client base today and will have a 69% client base once the get FDA approval for Roche and Bayers generic strips. This will leave all competitors in the dust. Nobody is going to toss their perfectly good monitors away. Think how comfy people are with their I phones. Their blood testing instrument is even more personal!